Acepodia在 2025年 AACR年会上展示抗体双重药物偶联（AD2C）技术的临床前数据-动脉网

Acepodia Presents Preclinical Data on Antibody-Dual-Drugs Conjugation (AD2C) technology at AACR Annual Meeting 2025

CISION 等信源发布 2025-04-21 19:00



可切换为仅中文







ALAMEDA, Calif.

阿拉米达，加利福尼亚州

and

和

TAIPEI

台北

，

April 21, 2025

2025年4月21日

/PRNewswire/ -- Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its proprietary dual-payload antibody-drug conjugate (AD2C) for hepatocellular carcinoma (HCC). The data will be featured at the American Association for Cancer Research (AACR) Annual Meeting 2025, which will take place from .

/PRNewswire/ -- Acepodia（6976:TT）今天宣布展示新的临床前数据，重点介绍其专有的双载荷抗体药物偶联物（AD2C）用于肝细胞癌（HCC）的治疗。这些数据将在美国癌症研究协会（AACR）2025年年会上发布，会议将于举行。

April 25 to April 30, 2025

2025年4月25日至2025年4月30日

在

Chicago, Illinois

伊利诺伊州芝加哥市

。

The poster presentation, titled 'Development of dual-payload anti-GPC3 antibody-drug conjugate by dual-payload antibody conjugation (AD2C) platform for hepatocellular carcinoma treatment,' showcases the company's next-generation ADC generated using Acepodia's AD2C platform. This platform allows for the conjugation of two distinct payloads to a single antibody without the need of antibody engineering or enzymatic conjugation.

海报展示标题为“通过双载荷抗体偶联（AD2C）平台开发针对肝细胞癌治疗的双载荷抗GPC3抗体药物偶联物”，展示了公司利用Acepodia的AD2C平台生成的下一代ADC。该平台能够在不需要抗体工程或酶促偶联的情况下，将两种不同的载荷偶联到单个抗体上。

AD2C, carrying payloads with different mechanisms of action, offer enhanced therapeutic potency by targeting diverse cell populations in heterogeneous tumors or overcoming resistance to single-payload therapy. .

AD2C通过携带具有不同作用机制的有效载荷，增强了治疗效力，可以靶向异质肿瘤中的多种细胞群体或克服对单载荷治疗的耐药性。

Presentation Details:

演示详情：

Session Title: Novel Drug Delivery Technologies

会议标题：新型药物递送技术

Session Category: Experimental and Molecular Therapeutics

会议类别：实验和分子治疗学

Date and Time:

日期和时间：

April 28, 2025

2025年4月28日

9:00 AM

上午9:00

–

12:00 PM CDT

中午12:00 CDT

Location: McCormick Place Convention Center,

地点：麦考密克会展中心，

Chicago, IL

伊利诺伊州芝加哥

Poster Board Number: 4 | Poster Section: 23

海报板编号：4 | 海报部分：23

Abstract Number: 1785

摘要编号：1785

'Acepodia's dual-payload ADC approach is designed to address key limitations of current single-payload therapies,' said Dr.

“Acepodia的双有效载荷ADC方法旨在解决当前单有效载荷疗法的关键局限性，”博士表示。

Sonny Hsiao

萧森友

, Chairman and CEO of Acepodia. 'By combining targeted delivery with enhanced cytotoxicity, this platform holds promise for more effective treatment of liver cancer and other solid tumors.' AD2C platform provides a novel, antibody-engineering-free approach to generate dual-payload ADCs, offering a potential solution to tumor heterogeneity and drug resistance in cancer treatment..

Acepodia的董事长兼首席执行官表示：“通过结合靶向递送和增强的细胞毒性，该平台有望为肝癌和其他实体瘤的治疗提供更有效的方案。” AD2C平台提供了一种新颖的、无需抗体工程的方法来生成双载荷ADC，为癌症治疗中的肿瘤异质性和耐药性问题提供了潜在解决方案。

The company's AD2C pipeline is part of its broader portfolio of conjugation technologies derived from the laboratory of Nobel Laureate Dr.

公司的AD2C管道是其从诺贝尔奖获得者博士实验室衍生出的更广泛结合技术组合的一部分。

Carolyn Bertozzi

卡罗琳·贝尔托齐

, enabling the site-specific delivery of therapeutic payloads using bioorthogonal click chemistry.

，利用生物正交点击化学实现治疗载荷的位点特异性递送。

About Acepodia

关于Acepodia

Acepodia (6976.TT) is a clinical-stage biotechnology company headquartered in

Acepodia（6976.TT）是一家总部位于临床阶段的生物技术公司，

Taipei

台北

and

和

Alameda, California

加利福尼亚州阿拉米达

, advancing innovative cancer and autoimmune disease therapies. The company's proprietary platforms leverage novel cell-based and antibody conjugation technologies to deliver potent, targeted, and safer therapies. Its conjugation platforms—originating from the lab of Nobel Laureate Carolyn Bertozzi—enable precise linking of antibodies or immune cells with cytotoxic payloads using click chemistry, creating a unique therapeutic potential for various cancer types and autoimmune diseases..

，推进创新的癌症和自身免疫疾病疗法。公司专有的平台利用新型细胞和抗体偶联技术，提供高效、靶向且更安全的治疗方案。其偶联平台源自诺贝尔奖得主卡罗琳·贝尔托齐的实验室，通过点击化学实现抗体或免疫细胞与细胞毒性载荷的精确连接，为多种癌症类型和自身免疫疾病创造了独特的治疗潜力。

For more information, visit

欲了解更多信息，请访问

https://www.acepodia.com/

SOURCE Acepodia Inc.

来源：Acepodia Inc.

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+